source
- Rezolute’s phase 3 trial of ersodetug meets primary endpoint in tumor hyperinsulinismRezolute reported that its phase 3 Uplift study of ersodetug in tumor hyperinsulinism achieved its primary endpoint. The trial required at least nine of 16 patients to show a 50% or greater reduct…
- Virtuoso Surgical receives FDA De Novo clearance for robotic bladder lesion removal systemVirtuoso Surgical's Virtuoso Endoscopy System received FDA De Novo authorization, marking the first device in a new classification for electromechanical surgical technologies that use robotic instr…